Literature DB >> 2037787

Zidovudine-associated embryonic toxicity in mice.

P Toltzis1, C M Marx, N Kleinman, E M Levine, E V Schmidt.   

Abstract

A novel toxicity associated with zidovudine (AZT), the standard antiviral therapy for infection with human immunodeficiency virus, is described. When AZT was administered to mice to evaluate its safety during gestation, the animals failed to complete pregnancy successfully. Mice receiving AZT during gestation yielded fewer fetuses (P = .003) and greater numbers of resorptions (P = .003) per pregnant mouse compared with untreated animals. Drug effects on adult mice were assessed to determine if toxicity could account for the pregnancy failures. However, adult animals receiving AZT demonstrated no adverse effects with regard to growth, food consumption, activity, or ovarian histology. A direct toxic effect of AZT on the mouse embryo was tested by cultivating single-cell fertilized oocytes in vitro in the presence of increasing concentrations of drug. Exposure to AZT was highly correlated with failure to develop to the blastocyst stage (P less than .001). These data indicate that AZT has a direct toxic effect on the developing mouse embryo. Further analysis of the nature of this toxicity may be important in designing less toxic antiretroviral agents and in planning future uses of AZT.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2037787     DOI: 10.1093/infdis/163.6.1212

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

Review 1.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

Review 2.  Human immunodeficiency virus/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals.

Authors:  Vitaly A Kushnir; William Lewis
Journal:  Fertil Steril       Date:  2011-06-30       Impact factor: 7.329

Review 3.  A risk-benefit assessment of zidovudine in the prevention of perinatal HIV transmission.

Authors:  M L Newell; D M Gibb
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

4.  Effect of zidovudine on preimplantation murine embryos.

Authors:  P Toltzis; T Mourton; T Magnuson
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

Review 5.  Guidelines for the use of zidovudine in pregnant women with HIV infection.

Authors:  M De Santis; G Noia; A Caruso; S Mancuso
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

6.  Amelioration of zidovudine-induced fetal toxicity in pregnant mice.

Authors:  S R Gogu; B S Beckman; K C Agrawal
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

7.  A role for retrotransposon LINE-1 in fetal oocyte attrition in mice.

Authors:  Safia Malki; Godfried W van der Heijden; Kathryn A O'Donnell; Sandra L Martin; Alex Bortvin
Journal:  Dev Cell       Date:  2014-05-29       Impact factor: 12.270

Review 8.  Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern?

Authors:  Claire Thorne; Marie-Louise Newell
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 9.  Antiviral and antiretroviral use in pregnancy.

Authors:  Deborah M Money
Journal:  Obstet Gynecol Clin North Am       Date:  2003-12       Impact factor: 2.844

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.